HRTX Heron Therapeutics Inc

Price (delayed)

$0.4774

Market cap

$90.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.17

Enterprise value

$205.88M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 33
Relative Profitability: Rel. Profitability: 20

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron ...

Highlights
The debt has declined by 20% year-on-year
The equity has surged by 132% year-on-year but it has declined by 36% since the previous quarter
Heron Therapeutics's net income has plunged by 53% from the previous quarter
Heron Therapeutics's EPS has decreased by 42% QoQ

Key stats

What are the main financial stats of HRTX

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
6.85%
1 week
-46.47%
1 month
-60.87%
1 year
-76.6%
YTD
-63.28%
QTD
-40.33%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$150.71M
Gross profit
$107.18M
Operating income
-$10.46M
Net income
-$30.94M
Gross margin
71.1%
Net margin
-20.5%
The operating income has dropped by 192% year-on-year
HRTX's operating margin has dropped by 188% year-on-year
The net margin has dropped by 58% since the previous quarter
Heron Therapeutics's net income has plunged by 53% from the previous quarter

Price vs fundamentals

How does HRTX's price correlate with its fundamentals

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
9.85
P/S
0.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.37
Heron Therapeutics's EPS has decreased by 42% QoQ
The equity has surged by 132% year-on-year but it has declined by 36% since the previous quarter
HRTX's price to sales (P/S) is 87% less than its 5-year quarterly average of 4.2 and 63% less than its last 4 quarters average of 1.5
HRTX's revenue is down by 2.7% since the previous quarter

Efficiency

How efficient is Heron Therapeutics business performance
The ROIC has plunged by 92% from the previous quarter
Heron Therapeutics's return on sales has shrunk by 90% QoQ
HRTX's ROA has shrunk by 52% QoQ

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 3.9% higher than its total liabilities
HRTX's total liabilities is down by 10% year-on-year
The current ratio has grown by 5% YoY and by 2% from the previous quarter
The equity has surged by 132% year-on-year but it has declined by 36% since the previous quarter
The debt to equity has soared by 58% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.